Loading
A phase 2 trial of tarlatamab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 is a phase 2, interventional study registered as NCT07203053 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 48 participants, started 2026-04-15 and due to reach its primary completion in 2029-10. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Cancer. Primary outcome: Overall survival rate at 12 months (12-month OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed ES-SCLC". Sites: France, Greece, Italy, Spain, Switzerland. No results are recorded here; the registry entry is the source.
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, Bispecific antibodies and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.